Travere Therapeutics (TVTX) Tops Q2 EPS by 16c

Travere Therapeutics (NASDAQ: TVTX) reported Q2 EPS of ($0.14), $0.16 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $114.4 million versus the consensus estimate of $99.25 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• JPMorgan Starts Kanzhun Ltd (2076:HK) at Overweight
• RBC Capital Downgrades Bucher Industries AG (BUCN:SW) (BCHHF) to Sector Perform